Phase 3 Clinical Trials – Page 3

Vertex’s Non-Opioid Pain Drug, Suzetrigine (VX-548), Shows Promising Results in Phase III Trials, Aiming for FDA Approval

8 months ago talkbio0Tagged Acute onset pain, Approved, non-opioid pain drug, Opioids, Phase 3 Clinical Trials, Suzetrigine, United States Food and Drug Administration, VX-548

Non-opioid pain drug, Suzetrigine (VX-548), Vertex Pharmaceuticals, Phase III trials, acute pain, FDA approval, opioid alternative

Lilly’s Omvoh Outperforms J&J’s Stelara in Phase III Crohn’s Disease Trial

8 months ago talkbio0Tagged Crohn 's disease, Eli, Eli Lilly, Inflammatory Bowel Diseases, mirikizumab, Phase 3 Clinical Trials, Stelara, ustekinumab

Omvoh (mirikizumab), Stelara (ustekinumab), Crohn’s disease, Phase III trial, Inflammatory bowel disease (IBD), Eli Lilly, Johnson & Johnson

Scholar Rock’s Stock Skyrockets 300% Following Successful Phase III Trial of Apitegromab for Spinal Muscular Atrophy

8 months ago talkbio0Tagged apitegromab, Biologics License Application, MAA, Phase 3 Clinical Trials, Scholar Rock, SMA, Spinal Muscular Atrophy, Stock Surge

Scholar Rock, Spinal Muscular Atrophy (SMA), Apitegromab, Phase III Trial, Stock Surge, Biologics License Application (BLA), Marketing Authorisation Application (MAA)

Zephyrm Seeks Hong Kong IPO to Fund Phase III Cell Therapy Trials

8 months ago talkbio0Tagged Cell Therapy, IPO, Kong listing, Phase 3 Clinical Trials, Zephyrm

Zephyrm, IPO, cell therapy, Phase III trials, Hong Kong listing

AbbVie’s Tavapadon Shows Promising Results in Phase III Trial for Parkinson’s Disease

8 months ago talkbio0Tagged AbbVie, Parkinson 's disease, Phase 3 Clinical Trials, Tavapadon, TEMPO-1

AbbVie, Tavapadon, Parkinson’s Disease, Phase III Trial, TEMPO-1, Cerevel Therapeutics

Daiichi Sankyo and Merck Achieve Phase III Success with HER3-Targeted ADC in Lung Cancer

9 months ago talkbio0Tagged Co., Daiichi, Deruxtecan, HER3-Targeted, HERTHENA-Lung02, Non-Small Cell Lung Carcinoma, patritumab, Phase 3 Clinical Trials, Sankyo, therapeutic autologous dendritic cells

Patritumab deruxtecan, HER3-targeted ADC, Non-small cell lung cancer (NSCLC), Phase III trial, HERTHENA-Lung02, Daiichi Sankyo, Merck & Co.

AstraZeneca’s Imfinzi Demonstrates Significant Survival Benefits in Muscle-Invasive Bladder Cancer

9 months ago talkbio0Tagged AstraZeneca, durvalumab, Event-Free Survival, Imfinzi, MIBC, muscle-invasive bladder cancer, NIAGARA, Overall Survival, perioperative, Phase 3 Clinical Trials

AstraZeneca, Imfinzi (durvalumab), Muscle-Invasive Bladder Cancer (MIBC), Perioperative Treatment, Event-Free Survival (EFS), Overall Survival (OS), NIAGARA Phase III Trial